Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression

S. Bomken; L. Buechler; K. Rehe; F. Ponthan; A. Elder; H. Blair; C. M. Bacon; J. Vormoor; O. Heidenreich

doi:10.1038/leu.2012.206

Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression

S. Bomken
, L. Buechler
, K. Rehe
, F. Ponthan
, A. Elder
, H. Blair
, C. M. Bacon
, J. Vormoor
, O. Heidenreich

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

28 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	718-721
Aantal pagina's	4
Tijdschrift	Leukemia
Volume	27
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1038/leu.2012.206
Status	Gepubliceerd - mrt. 2013
Extern gepubliceerd	Ja

Toegang tot document

10.1038/leu.2012.206

Citeer dit

@article{f2ece64c93d541da95cc26c82df749e6,

title = "Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression",

author = "S. Bomken and L. Buechler and K. Rehe and F. Ponthan and A. Elder and H. Blair and Bacon, \{C. M.\} and J. Vormoor and O. Heidenreich",

note = "Funding Information: We thank Christopher Baum and Olga Kustikova for their help with the ligation-mediated PCR and Martin Stanulla and Martin Schrappe for the provision of sample L4951. SB is funded by a Medical Research Council (MRC) Clinical Research Training Fellowship. The IVIS Spectrum was funded by a grant from the Wellcome Trust, grant 087961. Additional funding came from Leukaemia Lymphoma Research (LLR) and core infrastructure support from the North of England Children′s Cancer Research Fund (NECCR).",

year = "2013",

month = mar,

doi = "10.1038/leu.2012.206",

language = "English",

volume = "27",

pages = "718--721",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "3",

}

TY - JOUR

T1 - Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression

AU - Bomken, S.

AU - Buechler, L.

AU - Rehe, K.

AU - Ponthan, F.

AU - Elder, A.

AU - Blair, H.

AU - Bacon, C. M.

AU - Vormoor, J.

AU - Heidenreich, O.

N1 - Funding Information: We thank Christopher Baum and Olga Kustikova for their help with the ligation-mediated PCR and Martin Stanulla and Martin Schrappe for the provision of sample L4951. SB is funded by a Medical Research Council (MRC) Clinical Research Training Fellowship. The IVIS Spectrum was funded by a grant from the Wellcome Trust, grant 087961. Additional funding came from Leukaemia Lymphoma Research (LLR) and core infrastructure support from the North of England Children′s Cancer Research Fund (NECCR).

PY - 2013/3

Y1 - 2013/3

UR - https://www.scopus.com/pages/publications/84875231419

U2 - 10.1038/leu.2012.206

DO - 10.1038/leu.2012.206

M3 - Letter

C2 - 22858908

AN - SCOPUS:84875231419

SN - 0887-6924

VL - 27

SP - 718

EP - 721

JO - Leukemia

JF - Leukemia

IS - 3

ER -